Apg Asset Management N.V. Biomarin Pharmaceutical Inc Transaction History

Apg Asset Management N.V.

$36.1 Billion
Q4 2024

A detailed history of Apg Asset Management N.V. transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Apg Asset Management N.V. holds 132,987 shares of BMRN stock, worth $7.8 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

132,987

Previous 19,332 587.91%

Holding current value

$7.8 Million

Previous $1.36 Million 543.67%

% of portfolio

0.02%

Previous 0.01%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 13, 2025	BUY	$61.93 - $70.49 $7.04 Million - $8.01 Million	113,655 Added 587.91%	132,987 $8.74 Million
Q3 2024 Nov 14, 2024	SELL	$69.02 - $93.84 $21.8 Million - $29.6 Million	-315,559 Reduced 94.23%	19,332 $1.36 Million
Q2 2024 Aug 14, 2024	SELL	$74.43 - $92.22 $4.9 Million - $6.07 Million	-65,874 Reduced 16.44%	334,891 $27.6 Million
Q1 2024 May 14, 2024	SELL	$83.81 - $99.0 $1.45 Million - $1.71 Million	-17,252 Reduced 4.13%	400,765 $35 Million
Q4 2023 Feb 13, 2024	BUY	$76.22 - $98.51 $683,922 - $883,930	8,973 Added 2.19%	418,017 $40.3 Million
Q3 2023 Nov 14, 2023	SELL	$85.07 - $94.48 $1.74 Million - $1.93 Million	-20,447 Reduced 4.76%	409,044 $36.2 Million
Q2 2023 Aug 14, 2023	SELL	$86.68 - $100.3 $1.07 Million - $1.24 Million	-12,370 Reduced 2.8%	429,491 $37.2 Million
Q1 2023 May 12, 2023	SELL	$87.74 - $117.27 $2.43 Million - $3.25 Million	-27,679 Reduced 5.89%	441,861 $43 Million
Q4 2022 Feb 14, 2023	BUY	$80.93 - $108.63 $11.8 Million - $15.9 Million	146,206 Added 45.22%	469,540 $48.6 Million
Q3 2022 Nov 14, 2022	SELL	$82.16 - $96.94 $14.4 Million - $17 Million	-175,744 Reduced 35.21%	323,334 $28 Million
Q2 2022 Aug 12, 2022	SELL	$71.48 - $86.85 $1.8 Million - $2.18 Million	-25,154 Reduced 4.8%	499,078 $39.6 Million
Q1 2022 May 12, 2022	SELL	$74.28 - $92.69 $96,564 - $120,497	-1,300 Reduced 0.25%	524,232 $36.3 Million
Q4 2021 Feb 11, 2022	BUY	$71.72 - $91.47 $27.2 Million - $34.7 Million	379,100 Added 258.89%	525,532 $40.8 Million
Q3 2021 Nov 15, 2021	SELL	$74.77 - $85.47 $328,988 - $376,068	-4,400 Reduced 2.92%	146,432 $9.77 Million
Q2 2021 Aug 13, 2021	SELL	$75.51 - $84.79 $30.1 Million - $33.8 Million	-399,220 Reduced 72.58%	150,832 $10.6 Million
Q1 2021 May 14, 2021	BUY	$74.73 - $90.69 $8.23 Million - $9.99 Million	110,175 Added 25.05%	550,052 $35.3 Million
Q4 2020 Feb 12, 2021	BUY	$72.61 - $90.2 $8.06 Million - $10 Million	110,963 Added 33.74%	439,877 $31.5 Million
Q3 2020 Nov 12, 2020	BUY	$71.87 - $131.03 $2.02 Million - $3.69 Million	28,165 Added 9.36%	328,914 $21.3 Million
Q2 2020 Aug 14, 2020	BUY	$79.55 - $124.22 $3.55 Million - $5.55 Million	44,648 Added 17.43%	300,749 $33 Million
Q1 2020 May 15, 2020	BUY	$71.37 - $96.85 $13.7 Million - $18.6 Million	192,421 Added 302.17%	256,101 $21.6 Million
Q1 2020 May 14, 2020	SELL	$71.37 - $96.85 $8.75 Million - $11.9 Million	-122,628 Reduced 65.82%	63,680 $5.04 Million
Q3 2019 Nov 08, 2019	BUY	$67.4 - $85.11 $7.29 Million - $9.21 Million	108,228 Added 138.61%	186,308 $11.5 Million
Q2 2019 Aug 13, 2019	BUY	$80.35 - $93.9 $1.16 Million - $1.35 Million	14,400 Added 22.61%	78,080 $5.87 Million
Q4 2018 Feb 13, 2019	SELL	$80.14 - $106.07 $64,112 - $84,856	-800 Reduced 1.24%	63,680 $4.74 Million
Q2 2018 Aug 13, 2018	SELL	$76.01 - $99.03 $623,282 - $812,046	-8,200 Reduced 11.28%	64,480 $5.2 Million
Q4 2017 Jan 24, 2018	BUY	$80.76 - $95.13 $8,076 - $9,513	100 Added 0.14%	72,680 $5.4 Million
Q3 2017 Oct 19, 2017	BUY	$80.6 - $94.95 $5.85 Million - $6.89 Million	72,580	72,580 $6.76 Million

Others Institutions Holding BMRN

# of Institutions

631

Shares Held

184M

Call Options Held

Put Options Held

1.67M

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $10.9B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Apg Asset Management N.V., based on Form 13F filings with the SEC.

News

Stay updated on Apg Asset Management N.V. with notifications on news.

Account

Apg Asset Management N.V. Biomarin Pharmaceutical Inc Transaction History